NewYork-Presbyterian, in partnership with Weill Cornell Medicine and Columbia University, remains at the forefront of clinical research related to pulmonary hypertension. Our experts are responsible for some of the earliest genetic studies in the field along with ground-breaking clinical trials evaluating new medical treatments—including the first drug approved for pulmonary hypertension (intravenous epoprostenol) in 1995.
Heart Failure Research Institute
Advancing the understanding, prevention, and treatment of heart failure through research
Pulmonary Hypertension
Advancing Precision Medicine
Dr. Evelyn Horn and colleagues are recognized as leaders for their hemodynamic approach to complex pulmonary hypertension and right heart dysfunction, be it Group 1-5 or mixed group taxonomies. Our team has been part of the 7 center NIH study (PVDOMICS), applying extensive clinical phenotyping inclusive of multidimensional imaging, cutting-edge physiological testing in the cath lab, exercise testing, and precision medicine in the assessment of pulmonary vascular disease and right heart failure. We have the benefit of close collaboration with colleagues at the PVDOMICS sites, our expert CV imagers, and the Englander Institute for Precision Medicine. Explore our work below.
Our Research
Study highlights
Heterogeneity in Group 1 PH
Increasingly, Group 1 PAH with distinct CV and pulmonary phenotypes have been appreciated in current cohorts distinct from younger historic PAH. Current algorithms recommend more cautious use of PAH therapies in these groups due to potential worsening of LA hypertension in CV patients and worsened V/Q mismatch in chronic lung patients. In PVDOMICS we assessed them as Mixed Groups 1,2 and 1,3 with appropriate physiology beyond mere co-morbidities.
Aging and the cardiopulmonary system in pulmonary Vascular disease
Overlapping with above, markers of senescence are more likely to be associated with cardiovascular and pulmonary cohorts and as the world of senescence biology expands, likely to have meaningful expression here.
Metabolomics of RV dysfunction
RVF has a different metabolic expression and a better understanding of the peripheral expression of such vs gradients across the pulmonary circulation.
Hemodynamic monitoring in Cpc-PH with cardiomems
Increasingly our PH-HFpEF are getting cardiomems. As abnormal pulmonary capacitance is the pulsatile load contributing to RV failure and is dictated by SV/PA PP, aside from monitoring filling pressure trends, we can analyze effective pulmonary capacitance.
Atrial remodeling
Most of the focus re cardiac remodeling has been at the ventricular level but evidence suggests that RA for pulmonary hypertension and LA for PH-HFpEF & VHD, particularly with Cpc-PH may offer some of the hidden clue(s).
CTD and its expression in heart and lungs
What are we missing when we don’t look: 1) Paucity immune pathology ; 2) anti endothelial antibodies with similarities to antibody mediated rejection; 3) possible presence of complement mediated, interferon related pathways. Additionally, can we learn anything with use of microvascular assessment
Recent publications
Sitbon O, Sahay S, Escribano Subías P, Zolty RL, Kingrey JF, Ryan JJ, Sobol I, Sood N, Benza RL, Channick RN, Chin KM, Frantz RP, Ghofrani HA, Hemnes AR, McLaughlin VV, Vachiéry JL, Zamanian RT, Ter Veer A, Roscigno RF, Mottola D, Parsley E, Aranda R, Zisman LS, Howard LS; TORREY Study Investigators. Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study. Adv Ther. 2025 Oct;42(10):5104-5123. doi: 10.1007/s12325-025-03297-2. Epub 2025 Aug 11. PMID: 40788460; PMCID: PMC12474731.
Reddy YNV, Asokan AK, Frantz RP, Hemnes A, Hassoun PM, Barnard J, Horn E, Leopold JA, Rischard F, Rosenzweig EB, Hill NS, Erzurum SC, Beck GJ, Finet JE, Grunig G, Jellis CL, Mathai SC, Simpson CE, Tang WHW, Nair KS, Borlaug BA. Metabolomic Evidence of Biological Overlap with Heart Failure with Preserved Ejection Fraction in a Subset of Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2025 Sep;211(9):1701-1713. doi: 10.1164/rccm.202501-0034OC. PMID: 40504754; PMCID: PMC12432440.
Mukherjee M, Jani VP, Osgueritchian R, Mombeini H, Abidov A, Beck G, Erzurum S, Frantz RP, Hassoun PM, Hemnes AR, Hill NS, Horn EM, Kim J, Kwon D, Larive AB, Leary PJ, Leopold JA, Mathai SC, Mehra R, Park MM, Rosenzweig EB, Tang WHW, Jellis CL, Rischard FP, Badagliacca R; Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics Network. Echocardiographic Parameters and Risk Prediction in Pulmonary Arterial Hypertension: Insights From the Redefining Pulmonary Hypertension Through Pulmonary Vascular Disease Phenomics Network. Chest. 2025 Aug;168(2):502-519. doi: 10.1016/j.chest.2025.04.007. Epub 2025 Apr 12. PMID: 40222714; PMCID: PMC12405913.
Reddy YNV, Frantz RP, Hassoun PM, Hemnes A, Horn E, Leopold JA, Rischard F, Rosenzweig EB, Hill NS, Erzurum SC, Beck GJ, Finet JE, Jellis CL, Mathai SC, Mehra R, Tang WHW, Borlaug BA; PVDOMICS Study Group. Left Heart Abnormalities in Patients With Lung Disease, OSA, and Chronic Thromboemboli at Risk for or With Known Pulmonary Hypertension. Circ Heart Fail. 2025 Aug;18(8):e012912. doi: 10.1161/CIRCHEARTFAILURE.125.012912. Epub 2025 May 29. PMID: 40438933; PMCID: PMC12353934.
Manca P, Nuzzi V, Lucchino A, Rugiano G, Mulè M, Carvelli A, Cannata S, Sciacca S, Parisi F, Sorrentino S, Faletra FF, Colombo PC, Cipriani MG. Right ventricular global work efficiency: A reliable non-invasive estimate of right ventricular contractility. ESC Heart Fail. 2025 Oct;12(5):3719-3730. doi: 10.1002/ehf2.15354. Epub 2025 Jul 3. PMID: 40607591; PMCID: PMC12450761.
Echo-Doppler Predictors of Residual Pulmonary Hypertension After Pulmonary Thromboendarterectomy
Oliveros E, Jonnalagadda A, Pietrowicz R, Mauri M, Zhao H, Maruthi R, Saunders H, Lakhter V, Brailovsky Y, Bashir R, Sadek A, Vaidya A, Forfia P. Echo-Doppler Predictors of Residual Pulmonary Hypertension After Pulmonary Thromboendarterectomy. J Clin Med. 2025 Aug 12;14(16):5705. doi: 10.3390/jcm14165705. PMID: 40869530; PMCID: PMC12386797.
Reddy YNV, Frantz RP, Dubrock HM, Hemnes AR, Horn EM, De Marco T, Burger C, Mathai SC, Kawut SM, Borlaug BA; PHAR investigators. Attenuated benefit to vasodilators in patients with pulmonary arterial hypertension and high probability of heart failure with preserved ejection fraction. Eur Respir J. 2025 Sep 17;66(3):2500880. doi: 10.1183/13993003.00880-2025. PMID: 40639872.
Villar-Calle P, Pai V, Zhang RS, Reza M, Jin L, Axman R, Falk Z, Falco G, RoyChoudhury A, Chen S, Mosadegh B, Kodali SK, Khalique OK, Horn EM, Weinsaft JW, Kim J. Nonischemic Septal Fibrosis in Functional Tricuspid Regurgitation Provides Incremental Stratification of Adverse Remodeling and Prognosis. JACC Cardiovasc Imaging. 2025 Sep;18(9):959-969. doi: 10.1016/j.jcmg.2025.03.015. Epub 2025 Jul 3. PMID: 40608040; PMCID: PMC12362310.
Loneliness and Risk of 30-Day Hospital Readmission After Acute Myocardial Infarction
Acker C, Soroka O, Sterling MR, Goyal P, Safford MM, Pinheiro LC. Loneliness and Risk of 30-Day Hospital Readmission After Acute Myocardial Infarction. Med Care. 2025 Sep 15. doi: 10.1097/MLR.0000000000002217. Epub ahead of print. PMID: 40971549.
Pulmonary Artery Size on CT Associates with Mean Pulmonary Artery Pressure and Mortality
Couch TJ, Beck GJ, Rozenzweig EB, Carr JJ, Erzurum SC, Frantz RP, Hassoun PM, Hill NS, Horn EM, Lempel JK, Leopold JA, Nian H, Ray DN, Rischard FP, Schwalbach KT, Terry JG, Hemnes AR. Pulmonary Artery Size on CT Associates with Mean Pulmonary Artery Pressure and Mortality. Ann Am Thorac Soc. 2025 Oct 15. doi: 10.1513/AnnalsATS.202507-831OC. Epub ahead of print. PMID: 41092241.
Atrial Fibrillation Worsens Right Ventricular Dysfunction and Outcomes in Acute Pulmonary Embolism
Mallery Q, Choi MH, Koura S, Greathouse F, Clarke J, Gadhoke N, Sharma A, Elkaryoni A, Desai P, Brailovsky Y, Darki A. Atrial Fibrillation Worsens Right Ventricular Dysfunction and Outcomes in Acute Pulmonary Embolism. Am J Cardiol. 2025 Oct 6;257:153-158. doi: 10.1016/j.amjcard.2025.09.045. Epub ahead of print. PMID: 41045956.
Appropriateness of Antiplatelets and Anticoagulants Among Older Adults Experiencing Falls
Klickstein LC, Niznik J, Branham V, George H, Meyer ML, Busby-Whitehead J, Davenport K, Roberts E, Goyal P, Goldberg E, Casey MF. Appropriateness of Antiplatelets and Anticoagulants Among Older Adults Experiencing Falls. J Am Geriatr Soc. 2025 Sep 27. doi: 10.1111/jgs.70127. Epub ahead of print. PMID: 41014071.
Representation of Older Adults in the AHA/ACC/HFSA Guideline for the Management of Heart Failure
Jamil Y, El Ghazawi A, Farhat K, Nouri A, Goyal P, Damluji AA, Nanna MG, Samsky MD. Representation of Older Adults in the AHA/ACC/HFSA Guideline for the Management of Heart Failure. JACC Adv. 2025 Oct 4:102135. doi: 10.1016/j.jacadv.2025.102135. Epub ahead of print. PMID: 41128709.
Incident Heart Failure in Adults With Mild to Moderate Chronic Kidney Disease
Girouard MP, Go AS, Liu JY, Parikh RV, Tan TC, Lee ES, Sun G, Halaseh R, Bhatt AS, Pravoverov L, Zheng S, Svetlichnaya J, Fitzpatrick JK, Avula HR, Lee KK, Adatya S, Ouyang D, Goyal P, Sandhu AT, Ambrosy AP. Incident Heart Failure in Adults With Mild to Moderate Chronic Kidney Disease. JACC Heart Fail. 2025 Aug 18:102616. doi: 10.1016/j.jchf.2025.102616. Epub ahead of print. PMID: 40888788.
Fudim M, Mehra MR, Damman K, Uriel N, Kalra PR, Sweeney F, Carmody D, Tucker J, Greene BR, Testani JM; Future HF Portfolio Investigators. Derivation of a Personalized Congestion Score Using a Chronic Implantable Inferior Vena Cava Management System in Heart Failure: An Analysis from the FUTURE-HF Trial Portfolio. J Card Fail. 2025 Sep 28:S1071-9164(25)00430-0. doi: 10.1016/j.cardfail.2025.09.018. Epub ahead of print. PMID: 41027509.
Park CM, Balkan L, Ringel JB, Shikany J, Bostick R, Judd SE, Jonas C, Arora P, Brown TM, Durant R, Hummel S, Jackson EA, Sterling MR, Demmer R, Yuzefpolskaya M, Levitan EB, Safford MM, Goyal P. Dietary Inflammatory Score and Incident Heart Failure in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. J Card Fail. 2025 Sep;31(9):1440-1449. doi: 10.1016/j.cardfail.2024.12.009. Epub 2025 Jan 14. PMID: 39818266; PMCID: PMC12256639.
Social Drivers of Health in Heart Failure Trials: An Analysis From the Heart Failure Collaboratory
DeFilippis EM, Blumer V, Makuvire TT, Echols MR, Adamson PB, Solomon S, Pina IL, Stein KM, Vaduganathan M, Walsh MN, Vardeny O, Jessup M, Yancy CW, Lindenfeld J, O'Connor CM, Fiuzat M. Social Drivers of Health in Heart Failure Trials: An Analysis From the Heart Failure Collaboratory. JACC Heart Fail. 2025 Sep;13(9):102546. doi: 10.1016/j.jchf.2025.102546. Epub 2025 Jul 17. PMID: 40680703.
Tamura S, Akita K, Fifer MA, Tower-Rader A, Maurer MS, Shimada YJ. Endothelial Cell-Related Proteins in Plasma Predict Major Adverse Cardiovascular Events and Worsening Heart Failure in Patients With Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2025 Oct 21;14(20):e042887. doi: 10.1161/JAHA.125.042887. Epub 2025 Oct 9. PMID: 41065251.
